These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 26774135

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE, Nuding MA.
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [Abstract] [Full Text] [Related]

  • 3. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC.
    J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
    Trevisson E, Cassina M, Opocher E, Vicenzi V, Lucchetta M, Parrozzani R, Miglionico G, Mardari R, Viscardi E, Midena E, Clementi M.
    J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1.
    Mehlan J, Schüttauf F, Salamon JM, Kordes U, Friedrich RE, Mautner VF.
    Anticancer Res; 2019 Feb; 39(2):827-831. PubMed ID: 30711963
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm.
    Caen S, Cassiman C, Legius E, Casteels I.
    Eur J Paediatr Neurol; 2015 Jul; 19(4):415-22. PubMed ID: 25797697
    [Abstract] [Full Text] [Related]

  • 12. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
    Thiagalingam S, Flaherty M, Billson F, North K.
    Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
    [Abstract] [Full Text] [Related]

  • 13. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
    Prada CE, Hufnagel RB, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, Schorry EK.
    J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
    [Abstract] [Full Text] [Related]

  • 14. The Utility of Early Brain MRI for Patients with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Long-Term Follow-Up in a Tertiary Referral Hospital.
    Rony C, Aharoni S, Halevy A.
    Neuropediatrics; 2022 Oct; 53(5):370-375. PubMed ID: 35381604
    [Abstract] [Full Text] [Related]

  • 15. Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.
    Arnljots U, Nilsson M, Bolzani R, Benassi M, Sandvik U, Munoz DM, Blomgren K, Hellgren K.
    PLoS One; 2024 Oct; 19(7):e0305548. PubMed ID: 38990917
    [Abstract] [Full Text] [Related]

  • 16. The role of visual electrodiagnostics in management of children with neurofibromatosis type 1.
    Tekavčič Pompe M, Pečarič Meglič N, Šuštar Habjan M.
    Doc Ophthalmol; 2023 Apr; 146(2):121-136. PubMed ID: 36652041
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.